Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Omnexel 400 micrograms prolonged release tablets, film-coated
Medicines register · Ireland

Omnexel 400 micrograms prolonged release tablets, film-coated

Authorisation PPA1463/025/001 · IMED Healthcare Ltd.,

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
IMED Healthcare Ltd., (all products →)
Active substance
Tamsulosin hydrochloride
Clinical trials
15 clinical trials →
Dosage form
Prolonged-release tablet
Route of administration
Oral use
ATC codes
G04CA, G04CA02
First authorised
28/08/2009
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Parallel importation notified in accordance with Article 76(3) of Directive 2001/83/EC

Tamsulosin hydrochloride: supply and approvals

27 authorised products on the HPRA list contain Tamsulosin hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Parallel import (PPA). A parallel product authorisation: the HPRA allows this product to be imported from another EU or EEA country and sold in Ireland. It has been authorised for 17 years (since 28 August 2009). The HPRA list does not say whether it is on sale.

Other medicines with Tamsulosin hydrochloride in Ireland

26 other products on the HPRA list contain Tamsulosin hydrochloride, from 13 licence holders; 11 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Combodart 0.5 mg/ 0.4 mg hard capsulesGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Dutasteride/Tamsulosin Hydrochloride 0.5 mg/0.4 mg hard capsulesAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Dutasteride/Tamsulosin Rowa 0.5 mg/0.4 mg hard capsules.Rowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Dutasteride/Tamsulosin hydrochloride 0.5 mg /0.4 mg hard capsulesViatris LimitedNational authorisation (PA)Marketed
Dutasteride/Tamsulosin hydrochloride Pinewood 0.5 mg/0.4 mg hard capsulesPinewood Laboratories LtdNational authorisation (PA)Marketed
Omnexel®, 400 micrograms prolonged release tablets, film-coatedAstellas Pharma Co. LimitedNational authorisation (PA)Marketed
TAMSU 400 micrograms modified-release capsules, hardRowex Limited,National authorisation (PA)Marketed
Tamnexyl XL 400 micrograms prolonged-release tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Tamnic 400 micrograms Modified-release Capsules, hardClonmel Healthcare LtdNational authorisation (PA)Marketed
Tamsulosin 400 micrograms Modified-release Capsules, HardViatris LimitedNational authorisation (PA)Marketed
Vesomni 6 mg/0.4 mg modified-release tabletsAstellas Pharma Co. LimitedNational authorisation (PA)Marketed
Combodart 0.5 mg/ 0.4 mg hard capsulesIMED Healthcare Ltd.,Parallel import (PPA)Not stated

All 27 products with Tamsulosin hydrochloride →

Other substances in ATC group G04CA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group G04CA with this product:

Dutasteride (6) · Terazosin (5) · Silodosin (4) · Alfuzosin hydrochloride (3)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

IMED Healthcare Ltd., holds 178 products on the HPRA list, with 119 different active substances; 1 of the products is marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.